PH Pharmaceuticals, Inc.
Founder, Chairman and CEO – 7/1/04 to present
Technology – PH Pharmaceuticals (PHP) has an issued patent on pharmaceutical aerosol technologies capable of mitigating or reversing the pulmonary clearance defects associated with cystic fibrosis (CF). The technology was discovered by Dr. George Scheele and his coworkers at Harvard Medical School based on 14 papers published between 1990 and 2001. These studies defined the ultimate biochemical deficiency associated with CF. A synopsis of these studies may be found under Scientist.
Proof of Concept Human Trials – Under the supervision of Dr. Joseph Pilewski at the University of Pittsburgh Medical Center, IRB-sponsored “Proof-of-Concept” trials in cystic fibrosis patients have demonstrated both the safety and efficacy of the PHP technology. Proof of Concept trials continue in an effort to determine the efficacy of PHP's technology in subgroups of CF patients.
Strategic Partnership - A strategic partnership has been formed between PHP and the Battelle Corporation in Columbus , OH , to provide the commercial formulation and to conduct the animal toxicology studies as part of drug development activities to commercialize PHP's technology for the treatment of cystic fibrosis
Viral Shield Pharmaceuticals, Inc.
Chairman & CEO
In 2002 I founded Viral Shield Pharmaceuticals, Inc., with 2-Hydroxypropyl beta cyclodextrin anti-viral technology licensed from Johns Hopkins Medical Institutions. Over the past two years, we have met the following milestones:
Developed topical treatment products for Herpes labialis and Herpes genitalis. Phase IIA clinical trials will be conducted in Germany for Herpes genitalis and Hungary for Herpes labialis, starting in Q2, 2004, for European registration.
The first long-acting antiviral hand cream and skin lotion is currently under development.
Also under development are nasal/oral/pulmonary sprays for prevention and early treatment of Influenza, Parainfluenza and Respiratory Syncitial Virus (RSV)
Future efforts will develop microbicides to block the sexual transmission of:
Herpes Simplex Virus
Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV) and Hepatitis B & C Virus (HBV, HCV).
Non-viral sexually transmitted diseases (STD), including Chlamydia, Trichomonas, Gonorrhea and Haemophilus ducreyi
Chairman - 1/00 to present
In 2000 I founded NovaLife, Inc., an E-Commerce health-care company focused on (i) Anti-Aging skin-care products and (ii) health-care products designed to restore the radiance of skin and nails. Currently, I serve as Chairman of this company.
Health-care, skin-care and personal fulfillment products developed for North American and international distribution
Anti-Aging Skin-Care Regime™ formulated and developed for the commercial market:
Foam Cleansing Formula™
Skin Toner Formula™
Gentle Exfoliating Formula™
Skin Moisturizing Formula™
Skin Rejuvenating Formula™
Health-care products desined to restore the radiance of skin and nails:
Clear Nail Formula™
Skin Clear Formula™
La Jolla Biosciences, LLC
President and CEO, 7/99 to present
In-licensing and out-licensing of intellectual property
Strategic Marketing and Capital for the Biotechnology/Pharmaceutical Industry,
Global Solutions in Business, Marketing and Science
AlphaGene, Inc .
Chairman and Chief Scientific Officer, 11/93 - 2/98
President, and CEO, 11/93 - 6/97
In the early 1990s I moved from the academic world into the business world by founding AlphaGene, Inc., a genomics and proteomics company focused on the discovery of genes associated with disease states, particularly those in the brain including Alzheimer's disease, Parkinson's disease, temporal-lobe epilepsy, trauma and cancer. I served as Chairman, President and CEO of AlphaGene from 1993 through 1997.
Responsible for the strategic direction of the Company
Raised $10 million in four successful private placement financings
Prepared strategic business plans and marketing brochures.
Together, with Chief Financial Officer, prepared operating budgets, P&L statements, balance sheets, and financial projections.
Established initial operations in the Charlestown Navy Yard Biotech Park in 1994 (3,000 sq. ft.) and moved business to Woburn , MA to expand operations in 1996 (10,000 sq. ft. in 6/96; 15,000 sq. ft. in 9/97).
Supervised a recruitment program which increased the number of employees from three in 11/94 to 35, including eight Ph.D.s, in 6/97.
Responsible for presentations to investments bankers, the scientific community, and potential clients.
Supervised the establishment of five core technologies which enabled the first disease-based, full-length genomics platform, AlphaGenomicsT, for expressed human genes.
- Molecular Biology - Synthesis of Full-Length, EXpressed gene (FLEX™) libraries. This patented technology provides the first technology platform capable of synthesizing cDNA libraries with high concentrations of full-length genes.
- Gene Family Selection (FLEX-FamilySelect™) - Identifies new members of known gene families.
- Gene Expression (FLEXpression™) - Uses high density microarray technology on biochips to identify disease-related genes according to their differential expression between normal and diseased tissues.
- DNA sequencing (FLEX-AutoSeq™) - The first automated platform for rapidly obtaining high quality (6-10 fold coverage) DNA sequences in full-length cDNAs. Demonstrated throughput of 200 full-length genes per month.
- Bioinformatics (FLEX-IS™) - Patent pending technology developed to automatically analyze the structural and functional features of full-length genes. The front end configured with an ease-of-use, point-and-click, drag-and-drop, icon-based query engine that substitutes for standard query language. Together, these two innovative features enable advanced data mining/discovery by individual scientists at platform-independent, point-of-research work stations.
Supervised the acquisition of scientific proof of principle for each of the core technologies.
Implemented successful commercialization of the Company's technology:
- Genetics Institute contract signed in February, 1998.
- NEN Life Sciences contract signed in August, 1998.
"It is not the critic who counts. The credit belongs to the man who is actually in the arena; whose face is marred by the dust and sweat and blood; who, at the best, knows in the end the triumph of high achievement, and who, at worst, if he fails, at least fails while daring greatly; so that his place shall never be with those cold and timid souls who know neither victory or defeat."
Back To Top